Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHIA | Q9BZP6 | 9/20 | 0.43 |
| ▸ | CHIT1 | Q13231 | 8/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | CHI3L1 | P36222 | 1/20 | 0.41 |
| ▸ | CHI3L2 | Q15782 | 1/20 | 0.41 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL313877 | 0.84 | HRH3 (0.51) | PIK3CDGRIN2BNPC1RAB9A | |
| SCHEMBL5212497 | 0.84 | HRH3 (0.51) | CHIACHIT1SIGMAR1GRIN2BGFER | |
| Hydrochloric Acid SCHEMBL6340964 | 0.83 | HRH3 (0.50) | PIK3CDGRIN2BNPC1RAB9A | |
| Hydrochloric Acid SCHEMBL7221627 | 0.83 | HRH3 (0.50) | PIK3CDGRIN2BNPC1RAB9A | |
| SCHEMBL4903723 | 0.81 | DRD3 (0.44) | CHIACHIT1CHI3L1CHI3L2PIK3CD | |
| SCHEMBL9451529 | 0.81 | CHIA (0.54) | CHIACHIT1SIGMAR1GFERNPC1 | |
| SCHEMBL3085819 | 0.79 | SIGMAR1 (0.48) | SIGMAR1 | |
| SCHEMBL31455232 | 0.77 | TAS2R14 (0.41) | CHIACHIT1SIGMAR1CHI3L1CHI3L2 | |
| SCHEMBL31455533 | 0.74 | ALDH1A1 (0.39) | CHIACHIT1SIGMAR1CHI3L1CHI3L2 | |
| SCHEMBL1968987 | 0.73 | CHIA (0.54) | CHIACHIT1SIGMAR1CHI3L1CHI3L2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080108611-A1 | SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-08 | — | — | US | claimed |
| WO-2007084815-A2 | SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-26 | — | — | WO | claimed |
| EP-1765803-B1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| EP-1765803-B1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA NV (BE) | 2016-03-09 | — | — | EP | disclosed |
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-7799824-B2 | Quaternary salt CCR2 antagonists | ORAPHARMA, INC. (US) | 2010-09-21 | — | — | US | disclosed |
| US-20080108611-A1 | SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-08 | — | — | US | disclosed |
| WO-2007084815-A2 | SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-07-26 | — | — | WO | disclosed |
| EP-1765803-A1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-28 | — | — | EP | disclosed |
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | KENVUE BRANDS LLC | 2006-12-28 | — | — | US | disclosed |
| WO-2006012135-A1 | QUATERNARY SALT CCR2 ANTAGONISTS | JANSSEN PHARMACEUTICA, N. V. (BE) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108611-A1 | SUBSTITUTED THIENOPYRIMIDINE KINASE INHIBITORS | MAP4K2, MAP3K6, MAP3K2 | CHIA 3668/4885CHIT1 4729/4885SIGMAR1 4432/4885 |
| US-20060293379-A1 | Quaternary salt CCR2 antagonists | CCR2, CCR1, CXCR2 | CHIA 782/4885CHIT1 455/4885SIGMAR1 858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.